ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
about
Human breast cancer tissues contain abundant phosphatidylcholine(36∶1) with high stearoyl-CoA desaturase-1 expressionCharacterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3Estrogen receptor alpha gene amplification in breast cancer: 25 years of debateDetection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridizationComprehensive genome sequence analysis of a breast cancer ampliconPolysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.CARAT: a novel method for allelic detection of DNA copy number changes using high density oligonucleotide arrays.Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesGene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolaseContribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsA mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in miceFast and non-toxic in situ hybridization without blocking of repetitive sequencesLaser capture microdissection-guided fluorescence in situ hybridization and flow cytometric cell cycle analysis of purified nuclei from paraffin sections.Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness.Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples.Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma.Non-isotopic molecular cytogenetics in neuro-oncology.Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.Evaluation of a novel approach to circulating tumor cell isolation for cancer gene panel analysis in patients with breast cancer.HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimensSpecific genomic aberrations in primary colorectal cancer are associated with liver metastasesDetecting cancer gene networks characterized by recurrent genomic alterations in a population.Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Prognosis of lymph node-negative breast cancer: Association with clinicopathological factors and tumor associated gene expressionDual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization.Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic ImplicationsComparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.HER2: the neu prognostic marker for breast cancer.The HER-2/neu oncogene in tumors of the gastrointestinal tract.Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer.Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.Comprehensive copy number profiles of breast cancer cell model genomes.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisPrimary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.Duplication of C7orf58, WNT16 and FAM3C in an obese female with a t(7;22)(q32.1;q11.2) chromosomal translocation and clinical features resembling Coffin-Siris Syndrome.Predictive and prognostic markers for invasive breast cancer.
P2860
Q21090768-3A672252-F9C5-4313-B1FD-C68254E80528Q22008719-9C4331E5-EFCC-4C42-B0BB-25463293AFE0Q24273274-32852422-4F5C-478A-9D41-57874C4DE7D3Q24564349-76250D74-531C-4CEB-A063-5C5BAF06666AQ24618889-F2B67EEA-43C9-4A93-8D43-FA8CC95820D2Q24797806-930DD8E1-4806-46A7-ABB8-345471B1DF16Q25257143-3BCF7F42-A2AB-48AD-9F27-A8C1CE967EF5Q26823978-940253E2-0F59-424C-936D-9C7F484117A0Q28257362-08586386-F1D7-4A5E-9687-8397D26CC0BEQ28547357-A6B6BA9E-D235-4ACA-858E-3FCD422C4EF1Q28594190-5C2DBAE7-6A41-4F15-B85F-3530F4F54136Q28728860-289B4629-9AA2-47F8-AFCB-782D051F2FDFQ30883226-E306AA82-D532-4CC3-8ABB-CCF3374042ECQ30959521-D40FCE1B-71E7-466F-A9D0-C2652321DE08Q30986520-0C1DE68D-84BF-4B84-9296-1D84A2217185Q31029884-7FB6CDBE-101D-4916-A0E5-2B39EE22FE91Q31078568-6E4E0DEE-C9FB-43CF-AA91-322CE0C6EAD3Q31811177-0C4597A3-9BBF-45F9-829D-071946487DFBQ32126669-CB32C708-1F2C-49C1-8502-BDE29ECC6529Q33260375-9AB13135-693C-4EB4-AF0F-96B52C86A767Q33684887-7529B4B1-AF01-42C8-8DA8-BC101853C06AQ33711632-2B0783F9-D2A5-4063-865E-7A4FDCC1884AQ33761768-024338D7-2A5B-4ACC-9467-8BADF7CED079Q33808510-97E83F7D-C167-457D-8135-1D85F4EE061FQ33984756-CE8ACD2F-17D5-4F4F-8106-387F2D084ABCQ34010867-E35B597D-0CFA-4376-B5EA-FE58FB42F763Q34141617-73018041-6501-487C-9608-6FC59DCF5EA9Q34158575-FC992E7D-98D2-410D-92A5-5A05EC6FB185Q34173557-98DB53FE-27FD-4D2D-8960-4579664C6E6CQ34223494-E15A1C22-AF57-48CA-9D98-4F911282215CQ34247041-DC986FD4-300C-4BD9-A7AF-4EBA33061350Q34248406-F2F417B4-0CEF-4F3D-8A5C-42ECE175580EQ34311106-F2D56292-145C-4875-8E14-5712870EA1DBQ34400615-85EA6412-E79D-4B8A-8808-FE0844E09A13Q34433064-AC2C41D5-E693-4835-816D-427514D5A7BEQ34480698-67E7781A-64C2-4824-8683-40B2A813B975Q34493341-C4F1F63B-BD53-40C7-BCC0-E5E5A1A51505Q34493886-C162C983-AAF0-434A-8894-44D48AF0438CQ34540581-49156732-E415-4ABA-97E1-3550A844DA10Q34612314-483E800B-AE98-42BD-A154-A460E61500A3
P2860
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1992
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
@en
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
@nl
type
label
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
@en
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
@nl
prefLabel
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
@en
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
@nl
P2093
P2860
P356
P1476
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
@en
P2093
A Kallioniemi
F M Waldman
P2860
P304
P356
10.1073/PNAS.89.12.5321
P407
P577
1992-06-01T00:00:00Z